Phase 3 N=145 A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
Thermal Burns
Primary: Time to Complete Eschar Removal (in Days) — 0.99; 5.99 Days — p=0.0008
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=95 Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
Peripheral T Cell Lymphoma · Pediatric Hodgkin Lymphoma
Primary: Percentage of Participants Who Had One or More Serious or Non-serious Adverse Event Classified as Peripheral Neuropathy — 0; 0; 0; 0 Participants
Phase 1 N=4 MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0 Participants
N/A N=130 Master Study of the Acticor/Rivacor ICDs/CRT-Ds and the Plexa ProMRI S DX Lead
Heart Failure · Tachyarrhythmia
Primary: Cor Family-related Serious Adverse Device Effect (SADE)-Free Rate Until 3-month Follow-up — 122 Participants — p=0.05
Phase 2 N=488 Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Acute Respiratory Distress Syndrome · Critical Illness · Respiratory Failure
Primary: Days Alive and Free of Organ Support to Day 28 — 20.2; 20.5; 19.7; 18.4 days — p=0.65
Phase 2 N=38 Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
Primary: Proportion of Subjects With a Complete Response Rate (CR) at 1 Year of Therapy — 0.26 proportion of participants
N/A N=755 Patient-Centered Models of HCV Care for People Who Inject Drugs
Hepatitis C · Medication Adherence
Primary: Sustained Viral Response (SVR) — 226; 236 participants
N/A N=100 Virtual Visits for Postoperative Care Following Urogynecologic Surgery
Satisfaction, Patient
Primary: Patient Satisfaction — 75.18; 75.14 score on a scale
N/A N=250 Survey to Identify Substance Use in Teenagers and Adolescents
Anesthesia
Primary: Number of Participants With Adolescent and Parent Reported Alcohol, Drug, Vaping and Tobacco Usage — 1; 1; 0; 425 Participants
N/A N=50 LowCostomy: Dedicated Toward Creating a High-quality, Low-cost Colostomy Appliance for Those in Sub-Saharan Africa
Abdominal Site · Colostomy Site
Primary: Skin Irritation as Measured by Draize Score for Erythema and Edema — 0.86; 0.03; 0; 0.38 score on a scale — p=<0.0001
N/A N=235 Preferences for Open Vs. Endovascular Repair for Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Primary: Veteran Preference for Repair Type — 25; 25; 95; 80 Participants
Phase 3 N=523 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Schizophrenia · Schizophreniform Disorder · Bipolar I Disorder
Primary: Incidence of Adverse Events — 314 Participants
N/A N=31 Feasibility and Acceptability Off The Equus Effect
Social Skills · Emotional Dysfunction
Primary: Social Adjustment Scale-Self Report (SAS-SR) — 2.92; 2.92; 2.30; 2.32 score on a scale — p=<0.05
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
N/A N=408 Alcohol & Mobile Phone Study to Reduce High-risk Alcohol Use and Consequences
Alcohol; Use, Problem
Primary: Daily Drinking Questionnaire - Typical Number of Drinks Per Week — 13.51; 12.23; 10.70; 8.95 drinks — p=0.34